Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells

Cancer Research

Volumn 56, Issue 4, 1996, Pages 789-793

  Fukuda, Minoru ^a,c   Nishio, Kazuto ^b   Kanzawa, Fumihiko ^b   Ogasawara, Hayato ^b   Ishida, Tomoyuki ^b   Arioka, Hitoshi ^b   Bojanowski, Krzysztof ^b   Oka, Mikio ^c   Saijo, Nagahiro ^a,b  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c NAGASAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

6 FORMYLAMINO 12,13 DIHYDRO 1,11 DIHYDROXY 5H INDOLO[2,3 A][PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 GLUCOSIDE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; CISPLATIN; DNA TOPOISOMERASE; GYRASE INHIBITOR; IRINOTECAN; PACLITAXEL; UNCLASSIFIED DRUG; VINDESINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL KILLING; CROSS LINKING; CYTOTOXICITY; DNA REPAIR; DNA STRAND BREAKAGE; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARBAZOLES; CARCINOMA, SMALL CELL; CELL DIVISION; CELL NUCLEUS; CELL SURVIVAL; CISPLATIN; DNA REPAIR; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME INHIBITORS; GLUCOSIDES; HUMANS; LUNG NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0030068657     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Ohno, R., Okada, K., Masaoka, T., Kuramoto, A., Arima, T., Yoshida, Y., Ariyoshi, H., Ichimaru, M., Sasaki, Y., Oguro, M., Ito, Y., Morishima, Y., Yokomaku, S., and Ota, K. An early phase II study of CPT-11: a new derivative of camptothecin for the treatment of leukemia and lymphoma. J. Clin Oncol., 8: 1907-1912, 1990.
2. Masuda, N., Fukuoka, M., Kusunoki, Y., Matsui, K , Takifuji, N , Kudoh, S., Negoro, S., Nishioka, M., Nakagawa, K., and Takada, M. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol., 10: 1225-1229, 1992
3. Fukuoka M., Niitani, H., Suzuki, A , Motomiya, M., Hasegawa, K , Nishiwaki, Y., Kuriyama, T., Ariyoshi, Y., Negoro, S., Masuda, N , Nakajima, S., and Taguchi, T. A phase II study of CPT-11, a new derivative of camptothecin for previously untreated non-small-cell lung cancer. J. Clin. Oncol., 10: 16-20, 1992.
4. Shimada, Y., Yoshino, M., Wakui, A., Nakao, I., Futatsuki, K., Sakata, Y., Kambe, M., Taguchi, T., and Ogawa, N. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J. Clin. Oncol., 11: 909-913, 1993
5. Takeuchi, S., Takamizawa, H., Takeda, Y., Okawa, T., Tamaya, T., Noda, K., Sugawa, T., Sekiba, K., Yakushiji, M., and Taguchi, T. Clinical study of CPT-11, camptothecin derivative, on gynecological malignancy (Abstract 617) Proc. Am. Soc Clin. Oncol., 10: 189, 1991.
6. Yoshinari, T., Matsumoto, M., Arakawa, H , Okada, H., Noguchi, K., Suda, H., Okura, A , and Nishimura, K. Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(β-D-glucopyranosyl)-5H- indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity Cancer Res., 55: 1310-1315, 1995.
7. Evans, W. K., Shepherd, F A., Feld, R., Osoba, D., and Deboer, G. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J. Clin. Oncol., 3, 1471-1477, 1985.
8. Splinter, T., Kok, T., Kho, T., Lameris, H., Kate, F., Dalesio, O., Dolman, B., Palmen, F., Bouvy, J., Burghouts, J., Simonis, F., Harper, P., Rankin, E., Reijswoud, I , and Hoogenhuijze, J. A multicenter phase II trial of cisplatin and oral etoposide (VP-16) in inoperable non-small-cell lung cancer Semin. Oncol., 13 (Suppl. 3): 97-103, 1986.
9. Durand, R. E., and Goldie, J. H. Interaction of etoposide and cisplatin in an in vitro tumor model. Cancer Treat. Rep., 72 673-679, 1987.
10. Masuda, N., Fukuoka, M., Takada, M., Kusunoki, Y., Negoro, S , Matsui, K., Kudoh, S , Takifuji, N., Nakagawa, K., and Kishimoto, S CPT-11 in combination with displatin for advanced non-small-cell lung cancer. J. Clin. Oncol , 10: 1775-1780, 1992.
11. Fujiwara, Y., Yamakido, M., Fukuoka, M., Kudoh, S , Furuse, K., Ikegami, H., and Ariyoshi, Y. Phase II study of irinotecan (CPT-11) and cisplatin (CDDP) in patients with small-cell lung cancer. Proc. Am. Soc. Clin. Oncol., 13: 335, 1994.
12. Itoh, K., Takada, M., Kudo, S , Masuda, N., Nakagawa, K., Matsui, K., Takifuji, N., Kusunoki, Y., Fukuoka, M., and Kishimoto S. Synergistic effects of CPT-11 and cisplatin or etoposide on human lung cancer cell lines demonstrated by computer analysis (Abstract). Lung Cancer, 7 (Suppl.): 124, 1991.
13. Horiuchi, N., Nakagawa, K , Sasaki, Y , Minato, K , Fujiwara, Y , Nezu, K., Ohe, Y., and Saijo, N. In vitro antitumor activity of mitomycin C derivative (RM-49) and new anticancer antibiotics (FK973) against lung cancer cell lines determined by tetrazolium dye (MTT) assay Cancer Chemother. Pharmacol , 22: 246-250, 1988.
14. Steel, G. G., and Peckham, M. J. Exploitable mechanisms in combined radiotherapy-chemotherapy, the concept of additivity Int. J Radiat. Oncol. Biol. Phys., 5: 85-91, 1979.
15. Chun-Ming, T., Gazdar, A F., Venzon, D. J., Steinberg, S. M., Dedrick, R L., Mulshine, J. L., and Kramer, B S. Lack of in vitro synergy between etoposide and cis-diamminedichloroplatinum(II). Cancer Res., 49: 2390-2397, 1989
16. Bungo, M., Fujiwara, Y., Kasahara, K , Nakagawa, K., Ohe, Y., Sasaki, Y., Irino, S , and Saijo, N. Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in human non-small-cell lung cancer cell line relation to DNA damage and repair. Cancer Res., 50 2549-2553, 1990.
17. Zwelling, L. A., Anderson, T., and Kohn, K. W. DNA-protein and DNA interstrand cross-linking by cis- and trans-platinum(II)diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity. Cancer Res , 39: 365-369, 1979
18. Deffie, A. M., Batra, J. K., and Goldenberg, G. J. Direct correlation between DNA topoisomerase II activity and cytotoxicity in Adriamycin-sensitive and-resistant P388 leukemia cell lines Cancer Res., 49: 58-62, 1989.
19. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal. Biochem., 72: 248-254, 1976.
20. Liu, L. F., and Miller, K. G Eukaryotic DNA topoisomerase; two forms of type I DNA topoisomerase from HeLa cell nuclei. Proc. Natl. Acad. Sci. USA, 78: 3487-3491, 1981.
21. Chou, T-C., and Talalay, P. Quantitative analysis of dose-effects relationships: the combined effect of multiple drugs on enzyme inhibitors. Adv. Enzyme Regul., 22: 27-55, 1985
22. Kaneda, N., Nagata, H., Furuta, T , and Yokokura, T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res., 50: 1715-1720, 1990.
23. Rothenberg, M. L., Kuhn, J. G., Burris, H. A., III, Nelson, J., Eckardt, J. R., Tristan-Morales, M., Hilsenbeck, S. G., Weiss, G. R., Smith, L. S., Rodriguez, G. I., Rock, M K., and Von Hoff, D. D. Phase I and pharmacokinetic trial of weekly CPT-11 J Clin. Oncol., 11: 2194-2204, 1993.
24. Kano, Y., Suzuki, S., Akutsu, M., Suda, K. Inoue, Y., Yoshida, M., Sakamoto, S , and Miura, Y. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int S. Cancer, 50: 604-610, 1992.
25. Kudoh, S., Takada, M., Masuda, N., Nakagawa, K , Itoh, K., Kusunoki, Y., Negoro, S., Matsui, K., Takifuji, N., Morino, H , and Fukuoka, M. Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts. Jpn. J. Cancer Res., 84: 203-207, 1993.
26. Kim, R , Hirabayashi, N., Nishiyama, M., Jinushi, K., Toge, T., and Okada, K. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int. J. Cancer, 50: 760-766, 1992.
27. Kanzawa, F., Nishio, K., Kubota, N., and Saijo, N. Antitumor activities of a new indolocarbazole substance, NB-506-resistant cell line, SBC-3/NB Cancer Res., 55: 2806-2813, 1995
28. Hsiang, Y-H , Hertzberg, R., Hecht, S., and Liu, L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem., 260: 14873-14878, 1985.
29. Hsiang, Y-H., and Liu, L. F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res., 48: 1722-1726, 1988.
30. Hertzberg, R P., Caranfa, M. J., and Hecht, S. M. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry, 28: 4629-4638, 1989.
31. Hsiang, Y-H., Liu, L. F., Wall, M. E., Wani M. C., Nicholas, A. W., Manikumar, G., Kirschenbaum, S , Silber, R , and Potmesil, M. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res., 49: 4385-4389, 1989.
32. Jaxel, C., Kohn, K W., Wani, M. C , Wall, M. E., and Pommier, Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relaxation to antitumor activity. Cancer Res., 49: 1465-1469, 1989.
33. Bellon, S. F., Coleman, J. H., and Lippard, S. J DNA unwinding produced by site-specific intrastrand cross-links of the antitumor drug cis-diamminedichloroplatinum(II). Biochemistry, 30: 8026-8035, 1991.
34. Fichtinger-Schepman, A. M. J., van der Veer, J. L., den Hartog, J H. J., Lohman, P. H. M., and Reedijk, J. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry, 24: 707-713, 1985.
35. Gilbert, C. Cellular responses to cisplatin. J. Biol. Chem., 269: 787-790, 1994
36. Swinnen, L. J , Ellis, N. K., and Erichson, L. C Inhibition of cis-diammine-1,1-cyclobutane dicarboxylatoplatinum(II)-induced DNA interstrand cross-link removal and potentiation of cis-diammine-1,1-cyclobutane dicarboxy-latoplatinum(II) cytotoxicity by hydroxyurea and 1-β-D-arabinofuranosylcytosine. Cancer Res., 51: 1984-1989, 1991.
37. Esaki, T., Nakano, S , Tatsumoto, T., Kuroki-Migita, M., Mitsugi, K., Nakamura, M., and Niho, Y. Inhibition by 5-fluorouracil of cis-diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-1 human squamouscarcinoma cell line Cancer Res., 52, 6501-6506, 1992.
38. Eastman, A , and Schulte, N Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry, 27: 4730-4734, 1988.
39. Parker, R J., Eastman, A., Bostick, B. F., and Reed, E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J. Clin Invest , 87: 772-777, 1991.